Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Kavanagh

Showing results (1-10 of 193) with videos related to

Pageof 20
Sort By:
Clinical Medicine (London, England)|December 4, 2014
Protecting the kidney from complement: atypical haemolytic uraemic syndromeVicky Brocklebank, David Kavanagh
Pediatric Nephrology (Berlin, Germany)|June 8, 2010
Genetics and complement in atypical HUSDavid Kavanagh, Tim Goodship
The American Psychologist|September 11, 2013
David L. Rosenhan (1929-2012)Lee Ross, David Kavanagh
Nephron. Clinical Practice|November 13, 2010
Haemolytic uraemic syndromeDavid Kavanagh, Tim Goodship
Nephron. Experimental Nephrology|August 18, 2009
Pathogenesis of thrombotic microangiopathy: insights from animal modelsAnna Richards, David Kavanagh
Clinical Kidney Journal|October 6, 2017
Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panaceaVicky Brocklebank, David Kavanagh
Kidney International|December 16, 2011
Interpretation of genetic variants of uncertain significance in atypical hemolytic uremic syndromeDavid Kavanagh, Holly E Anderson
Current Opinion in Nephrology and Hypertension|December 20, 2007
Update on evaluating complement in hemolytic uremic syndromeDavid Kavanagh, Timothy H Goodship
Drug and Alcohol Review|March 27, 2009
Mailed treatment to augment primary care for alcohol disorders: a randomised controlled trialDavid Kavanagh, Jennifer M Connolly
Seminars in Immunopathology|January 10, 2018
Introduction to complement in health and disease: novel aspects and insightsB Paul Morgan, David Kavanagh
Pageof 20

Showing results (1-10 of 193) with videos related to

Sort By:
Pageof 20
Clinical Medicine (London, England)|December 4, 2014
Protecting the kidney from complement: atypical haemolytic uraemic syndromeVicky Brocklebank, David Kavanagh
Pediatric Nephrology (Berlin, Germany)|June 8, 2010
Genetics and complement in atypical HUSDavid Kavanagh, Tim Goodship
The American Psychologist|September 11, 2013
David L. Rosenhan (1929-2012)Lee Ross, David Kavanagh
Nephron. Clinical Practice|November 13, 2010
Haemolytic uraemic syndromeDavid Kavanagh, Tim Goodship
Nephron. Experimental Nephrology|August 18, 2009
Pathogenesis of thrombotic microangiopathy: insights from animal modelsAnna Richards, David Kavanagh
Clinical Kidney Journal|October 6, 2017
Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panaceaVicky Brocklebank, David Kavanagh
Kidney International|December 16, 2011
Interpretation of genetic variants of uncertain significance in atypical hemolytic uremic syndromeDavid Kavanagh, Holly E Anderson
Current Opinion in Nephrology and Hypertension|December 20, 2007
Update on evaluating complement in hemolytic uremic syndromeDavid Kavanagh, Timothy H Goodship
Drug and Alcohol Review|March 27, 2009
Mailed treatment to augment primary care for alcohol disorders: a randomised controlled trialDavid Kavanagh, Jennifer M Connolly
Seminars in Immunopathology|January 10, 2018
Introduction to complement in health and disease: novel aspects and insightsB Paul Morgan, David Kavanagh
Pageof 20